Last reviewed · How we verify
Meningococcal B Recombinant vaccine
Meningococcal B Recombinant vaccine is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 2 development. Also known as: rMenB+OMV.
At a glance
| Generic name | Meningococcal B Recombinant vaccine |
|---|---|
| Also known as | rMenB+OMV |
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults (PHASE4)
- Immunogenicity and Safety of MenB Vaccine in Pediatric Patients With Autoimmune Rheumatic Diseases (PHASE4)
- Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants (PHASE1)
- Infant Malaria Vaccine Schedule Optimization (PHASE2)
- Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali (PHASE1)
- Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination (PHASE2)
- Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ≥10 Years of Age (PHASE4)
- Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Meningococcal B Recombinant vaccine CI brief — competitive landscape report
- Meningococcal B Recombinant vaccine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Meningococcal B Recombinant vaccine
What is Meningococcal B Recombinant vaccine?
Meningococcal B Recombinant vaccine is a Biologic drug developed by GlaxoSmithKline.
Who makes Meningococcal B Recombinant vaccine?
Meningococcal B Recombinant vaccine is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
Is Meningococcal B Recombinant vaccine also known as anything else?
Meningococcal B Recombinant vaccine is also known as rMenB+OMV.
What development phase is Meningococcal B Recombinant vaccine in?
Meningococcal B Recombinant vaccine is in Phase 2.
Related
- Manufacturer: GlaxoSmithKline — full pipeline
- Also known as: rMenB+OMV
- Compare: Meningococcal B Recombinant vaccine vs similar drugs
- Pricing: Meningococcal B Recombinant vaccine cost, discount & access